T2 Biosystems Inc. (TTOO) 16.92 $TTOO
T2 Biosystems Announces 2015 First Quarter Conference Call Date
GlobeNewswire - Wed Apr 22, 5:30AM CDT
T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that it will release its 2015 first quarter results after the market closes on Tuesday, May 5, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Daylight Time on Tuesday, May 5, 2015, to discuss the financial results and other business developments.
TTOO: 16.92 (-0.56)
Is Great Basin Scientific Just Another Pump And Dump?
The GeoTeam - Seeking Alpha - Wed Apr 08, 12:57PM CDT
GeoInvesting is currently short Great Basic Scientific (NASDAQ: GBSN ), a rapid diagnostic medical test (Nucleic Acid Assay Testing) firm. We first alerted GeoInvesting premium members that we identified red flags associated with GBSN on March 30,...
GNMK: 10.69 (-0.24), GBSN: 4.17 (-0.53), BDX: 144.33 (-0.02), VIVO: 19.13 (+0.33), QDEL: 23.38 (-0.43), CPHD: 58.97 (+5.67), TTOO: 16.92 (-0.56), QGEN: 24.83 (-0.07), HOLX: 33.99 (+0.57), NSPH: 4.04 (+0.04)
Study Published in Future Microbiology Demonstrates Significant Cost and Survival Benefits for T2 Biosystems' T2Candida Panel for Sepsis
GlobeNewswire - Wed Apr 08, 5:30AM CDT
T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that results from an analysis on the impact of using the company's T2Candida Panel were published in Future Microbiology. The study, conducted by IMS Health, found that in a 500-bed hospital with an average of 5,100 symptomatic patients at high risk for developing a Candida infection, early detection with the utilization of T2Candida could provide an annual cost savings of approximately $5.8 million and the prevention of 60 percent of Candida-related deaths.
TTOO: 16.92 (-0.56)
T2 Biosystems: Impressive Opportunity With Sepsis Diagnosis
Capital Screen - at Seeking Alpha - Thu Mar 26, 7:01AM CDT
TTOO: 16.92 (-0.56)
T2 Biosystems, Inc. (TTOO) in Focus: Stock Jumps 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:21AM CDT
T2 Biosystems, Inc. (TTOO) was a big mover last session, as the company saw its shares rise 6% on the day.
TTOO: 16.92 (-0.56)
T2 Biosystems to Present at the Cowen Healthcare Conference
GlobeNewswire - Mon Mar 02, 5:30AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, is scheduled to present at the Cowen Healthcare Conference on Tuesday, March 3, 2015 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston.
TTOO: 16.92 (-0.56)
T2 Biosystems (TTOO) Crumbles: Stock Falls by 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:55AM CST
T2 Biosystems saw a big move last session, continuing the recent downward trend for the stock as the shares are down over 21% since Feb 5
TTOO: 16.92 (-0.56), LMNX: 16.10 (-0.18)
Accelerate Diagnostics - A Misleading Story Ripe For Decline
Shareholder Watchdog - Seeking Alpha - Wed Feb 18, 10:28AM CST
We ended our two-year hiatus from publishing on Seeking Alpha given a unique short opportunity that we think could decline by over 65%. Like our other reports, investors need to be very aware and cautious given the degree of risk we have identified....
ABT: 48.32 (-0.14), BDX: 144.33 (-0.02), AXDX: 23.50 (-0.12), TTOO: 16.92 (-0.56), NVS: 104.28 (-1.22), NSPH: 4.04 (+0.04)
T2 Biosystems' (TTOO) CEO John McDonough on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 17, 7:09PM CST
TTOO: 16.92 (-0.56)
T2 Biosystems misses by $0.01
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 3:03PM CST
TTOO: 16.92 (-0.56)
T2 Biosystems Reports 2014 Fourth Quarter, Full Year Results
GlobeNewswire - Tue Feb 17, 3:00PM CST
T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the fourth quarter and year ended December 31, 2014. Recent operational highlights included:
TTOO: 16.92 (-0.56)
T2 Biosystems Announces 2014 Fourth Quarter and Year-End Results Release and Conference Call Date
GlobeNewswire - Tue Feb 10, 6:25AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that it will release its 2014 fourth quarter and year-end financial results after the market closes on Tuesday, February 17, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Standard Time on Tuesday, February 17, 2015, to discuss the financial results and other business developments.
TTOO: 16.92 (-0.56)
T2 Biosystems' Lyme Disease Deal With Canon Is Bullish For Both Companies
JKenser - at Seeking Alpha - Fri Feb 06, 3:34PM CST
CAJ: 37.58 (+0.25), TTOO: 16.92 (-0.56)
T2 Biosystems to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 5:30AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 8:05 a.m. ET at the Waldorf Astoria Hotel in New York City.
TTOO: 16.92 (-0.56)
T2 Bio and Canon collaborate on rapid Lyme test
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:22AM CST
TTOO: 16.92 (-0.56)
T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease
GlobeNewswire - Tue Feb 03, 7:00AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO) a company developing innovative diagnostic products to improve patient health today announced that the company has entered into a multi-year, strategic agreement with Canon U.S. Life Sciences, Inc. to jointly develop a novel diagnostic test panel to rapidly detect Lyme disease, a tick-borne bacterial infection that, if left untreated, can cause chronic joint inflammation, neurological disorders and cognitive defects.
TTOO: 16.92 (-0.56)
IPO Lockup Expiration: T2 Biosystems, Inc.
Don Dion - at Seeking Alpha - Thu Jan 22, 12:15PM CST
TTOO: 16.92 (-0.56)
Obamacare's New Gold Standard: T2 Biosystems
Jeffrey Sovis - at Seeking Alpha - Wed Jan 21, 7:52AM CST
TTOO: 16.92 (-0.56)
Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections
GlobeNewswire - Tue Jan 13, 10:00AM CST
T2 Biosystems (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that a new article supporting the use of T2MR as a nanotechnology-based platform with the potential to significantly impact the field of diagnostics was published online today in The Journal of the American Medical Association (JAMA). The article, titled, "Nanotechnology," was co-authored by T2 Biosystems' Co-Founders Robert S. Langer, Sc.D., David H. Koch Institute Professor at the Massachusetts Institute of Technology and Ralph Weissleder, M.D., Ph.D., Thrall Professor of Radiology and Professor of Systems Biology at Harvard Medical School and Director of the Center for Systems Biology at Massachusetts General Hospital.
TTOO: 16.92 (-0.56)
Pivotal Data for T2Candida and T2Dx Published in Clinical Infectious Diseases
GlobeNewswire - Tue Jan 13, 5:30AM CST
- Study Demonstrated 91.1% Sensitivity and Specificity of 99.4% for Sepsis Pathogen Detection in 3-5 Hours Without the Need for Blood Culture -
TTOO: 16.92 (-0.56)
T2 Biosystems Announces 2015 First Quarter Conference Call Date
GlobeNewswire - Wed Apr 22, 5:30AM CDT
T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that it will release its 2015 first quarter results after the market closes on Tuesday, May 5, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Daylight Time on Tuesday, May 5, 2015, to discuss the financial results and other business developments.
TTOO: 16.92 (-0.56)
Is Great Basin Scientific Just Another Pump And Dump?
The GeoTeam - Seeking Alpha - Wed Apr 08, 12:57PM CDT
GeoInvesting is currently short Great Basic Scientific (NASDAQ: GBSN ), a rapid diagnostic medical test (Nucleic Acid Assay Testing) firm. We first alerted GeoInvesting premium members that we identified red flags associated with GBSN on March 30,...
GNMK: 10.69 (-0.24), GBSN: 4.17 (-0.53), BDX: 144.33 (-0.02), VIVO: 19.13 (+0.33), QDEL: 23.38 (-0.43), CPHD: 58.97 (+5.67), TTOO: 16.92 (-0.56), QGEN: 24.83 (-0.07), HOLX: 33.99 (+0.57), NSPH: 4.04 (+0.04)
Study Published in Future Microbiology Demonstrates Significant Cost and Survival Benefits for T2 Biosystems' T2Candida Panel for Sepsis
GlobeNewswire - Wed Apr 08, 5:30AM CDT
T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that results from an analysis on the impact of using the company's T2Candida Panel were published in Future Microbiology. The study, conducted by IMS Health, found that in a 500-bed hospital with an average of 5,100 symptomatic patients at high risk for developing a Candida infection, early detection with the utilization of T2Candida could provide an annual cost savings of approximately $5.8 million and the prevention of 60 percent of Candida-related deaths.
TTOO: 16.92 (-0.56)
T2 Biosystems: Impressive Opportunity With Sepsis Diagnosis
Capital Screen - at Seeking Alpha - Thu Mar 26, 7:01AM CDT
TTOO: 16.92 (-0.56)
T2 Biosystems, Inc. (TTOO) in Focus: Stock Jumps 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 8:21AM CDT
T2 Biosystems, Inc. (TTOO) was a big mover last session, as the company saw its shares rise 6% on the day.
TTOO: 16.92 (-0.56)
T2 Biosystems to Present at the Cowen Healthcare Conference
GlobeNewswire - Mon Mar 02, 5:30AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, is scheduled to present at the Cowen Healthcare Conference on Tuesday, March 3, 2015 at 10:00 a.m. EST at the Boston Marriott Copley Place in Boston.
TTOO: 16.92 (-0.56)
T2 Biosystems (TTOO) Crumbles: Stock Falls by 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:55AM CST
T2 Biosystems saw a big move last session, continuing the recent downward trend for the stock as the shares are down over 21% since Feb 5
TTOO: 16.92 (-0.56), LMNX: 16.10 (-0.18)
Accelerate Diagnostics - A Misleading Story Ripe For Decline
Shareholder Watchdog - Seeking Alpha - Wed Feb 18, 10:28AM CST
We ended our two-year hiatus from publishing on Seeking Alpha given a unique short opportunity that we think could decline by over 65%. Like our other reports, investors need to be very aware and cautious given the degree of risk we have identified....
ABT: 48.32 (-0.14), BDX: 144.33 (-0.02), AXDX: 23.50 (-0.12), TTOO: 16.92 (-0.56), NVS: 104.28 (-1.22), NSPH: 4.04 (+0.04)
T2 Biosystems' (TTOO) CEO John McDonough on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 17, 7:09PM CST
TTOO: 16.92 (-0.56)
T2 Biosystems misses by $0.01
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 3:03PM CST
TTOO: 16.92 (-0.56)
T2 Biosystems Reports 2014 Fourth Quarter, Full Year Results
GlobeNewswire - Tue Feb 17, 3:00PM CST
T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the fourth quarter and year ended December 31, 2014. Recent operational highlights included:
TTOO: 16.92 (-0.56)
T2 Biosystems Announces 2014 Fourth Quarter and Year-End Results Release and Conference Call Date
GlobeNewswire - Tue Feb 10, 6:25AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that it will release its 2014 fourth quarter and year-end financial results after the market closes on Tuesday, February 17, 2015. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Standard Time on Tuesday, February 17, 2015, to discuss the financial results and other business developments.
TTOO: 16.92 (-0.56)
T2 Biosystems' Lyme Disease Deal With Canon Is Bullish For Both Companies
JKenser - at Seeking Alpha - Fri Feb 06, 3:34PM CST
CAJ: 37.58 (+0.25), TTOO: 16.92 (-0.56)
T2 Biosystems to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 5:30AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 8:05 a.m. ET at the Waldorf Astoria Hotel in New York City.
TTOO: 16.92 (-0.56)
T2 Bio and Canon collaborate on rapid Lyme test
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:22AM CST
TTOO: 16.92 (-0.56)
T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease
GlobeNewswire - Tue Feb 03, 7:00AM CST
T2 Biosystems, Inc. (Nasdaq:TTOO) a company developing innovative diagnostic products to improve patient health today announced that the company has entered into a multi-year, strategic agreement with Canon U.S. Life Sciences, Inc. to jointly develop a novel diagnostic test panel to rapidly detect Lyme disease, a tick-borne bacterial infection that, if left untreated, can cause chronic joint inflammation, neurological disorders and cognitive defects.
TTOO: 16.92 (-0.56)
IPO Lockup Expiration: T2 Biosystems, Inc.
Don Dion - at Seeking Alpha - Thu Jan 22, 12:15PM CST
TTOO: 16.92 (-0.56)
Obamacare's New Gold Standard: T2 Biosystems
Jeffrey Sovis - at Seeking Alpha - Wed Jan 21, 7:52AM CST
TTOO: 16.92 (-0.56)
Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections
GlobeNewswire - Tue Jan 13, 10:00AM CST
T2 Biosystems (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that a new article supporting the use of T2MR as a nanotechnology-based platform with the potential to significantly impact the field of diagnostics was published online today in The Journal of the American Medical Association (JAMA). The article, titled, "Nanotechnology," was co-authored by T2 Biosystems' Co-Founders Robert S. Langer, Sc.D., David H. Koch Institute Professor at the Massachusetts Institute of Technology and Ralph Weissleder, M.D., Ph.D., Thrall Professor of Radiology and Professor of Systems Biology at Harvard Medical School and Director of the Center for Systems Biology at Massachusetts General Hospital.
TTOO: 16.92 (-0.56)
Pivotal Data for T2Candida and T2Dx Published in Clinical Infectious Diseases
GlobeNewswire - Tue Jan 13, 5:30AM CST
- Study Demonstrated 91.1% Sensitivity and Specificity of 99.4% for Sepsis Pathogen Detection in 3-5 Hours Without the Need for Blood Culture -
TTOO: 16.92 (-0.56)
